Insight

Rugengamanzi Eulade: Hodgkin’s Lymphoma in Tanzania according to HIV status during the HAART era

Photo taken from elevate.in

Jul 5, 2024, 14:21

Rugengamanzi Eulade: Hodgkin’s Lymphoma in Tanzania according to HIV status during the HAART era

Rugengamanzi Eulade, Oncologist at

“We have published:

‘A comparison of clinical profile and treatment outcome of Hodgkin’s Lymphoma in Tanzania according to HIV status during the HAART era’ in BMC Cancer.

Highlights

The 2-year OS rate for HIV-HL was 34%, while that for non-HIV-HL was 67%.

Among the HIV-HL patients, predictors of a poorer outcome were a CD4 count ≤ 200 cells/mm3 (P = 0.05), lack of HAART use (P = 0.00), and the use of HAART for ≤ 10 months (P = 0.00).

Conclusion: HIV positivity is still a poor prognostic factor.”

Rugengamanzi Eulade

Additional information.
Source: Rugengamanzi Eulade/LinkedIn

BMC Cancer cancer Christina V. Malichewe Emmanuel L. Lugina Emmanuel Mduma Eulade Rugengamanzi HIV Hodgkin's Lymphoma Mercy M. Mbai OncoDaily Oncology Rugengamanzi Eulade Samuel Thuo

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer